How to Avoid Insurance Denials for Prescribing a Biologic Without MTX in Concert
Should Patients with Rheumatic Disease Switch from Biologic to Biosimilar?
Safety, Tolerability & Pharmacodynamics of ABT-122 in Patients with RA
Biosimilars Great Debate: To Switch or Not?
HSCT for Severe Autoimmune Diseases
Sanofi to Invest Further in Biologics
Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment
U.S. Supreme Court Speeds Copycat Biologic Drugs to Market
Physician’s Choice: Factors That Influence First- & Second-Line Biologic Therapy in RA Patients
- 1
- 2
- 3
- …
- 10
- Next Page »